Whitehawk Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Whitehawk Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Whitehawk Therapeutics Inc WHWK.OQ reported a quarterly adjusted loss of 20 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -76 cents. The mean expectation of eight analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -40 cents to -22 cents per share.
Reported revenue was zero; analysts expected zero.
Whitehawk Therapeutics Inc's reported EPS for the quarter was a loss of 20 cents.
The company reported a quarterly loss of $16.64 million.
Whitehawk Therapeutics Inc shares had fallen by 11.1% this quarter and gained 68.2% so far this year.
FORECAST CHANGES
The mean earnings estimate of analysts had risen by about 9.3% in the last three months.
In the last 30 days, there have been no negative revisions of earnings estimates
RECOMMENDATIONS
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," 3 "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"
Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $7.50, about 45.7% above its last closing price of $4.07
This summary was machine generated from LSEG data August 6 at 02:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
Jun. 30 2026 | -0.30 | -0.20 | Beat |
Mar. 31 2026 | -0.36 | -0.32 | Beat |
Dec. 31 2025 | -0.15 | -0.34 | Missed |
Sep. 30 2025 | 0.07 | -0.26 | Missed |